Duodenal mucosal resurfacing (DMR), a new-style endoscopic procedure using hydrothermal energy to ablate this thickened layer ...

The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.

Short term trials with surrogate measures instead of hard outcomes are often used to study chronic diseases. The effects of an intervention may, however, take time to develop and persist after ...

Of these, 20% were GLP-1 drugs alone, with a host of other combinations such as GLP-1/gastric inhibitory peptide (GIP), GLP-1/glucagon, and GLP-1/amylin. IQVIA also found there were 50 other ...

Multi-modal data integration of single-nuclei RNA and ATAC sequencing with spatial transcriptomics, provides new molecular insights into gene regulatory networks driving cell state transitions in ...

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019. Yet the stock has since plummeted 61% from its peak value. Despite ...

Peptide receptor radiotherapy is a new treatment option for patients with high tumor content of somatostatin type 2 receptors and will be further developed in the future.

BPC-157, a pentadecapeptide derived from an endogenously occurring protein sequence in gastric juice, has garnered attention within the scientific community due to its hypothesized role in ...

Unravelling the causality between inflammatory bowel disease and polycystic ovary syndrome mediated by gut microbiota and blood metabolism: insights from two prospective cohort studies ...